ASCVD Risk Calculator
Estimates 10-year risk of a first atherosclerotic cardiovascular event (non-fatal MI, CHD death, or fatal/non-fatal stroke) using the ACC/AHA Pooled Cohort Equations. For primary prevention in adults aged 40–79 without prior ASCVD.
Calculate 10-Year ASCVD Risk
Enter patient demographics, lipid values, and clinical parameters below. This calculator implements the 2013 ACC/AHA Pooled Cohort Equations for adults aged 40–79 years without prior clinical ASCVD (no prior MI, stroke, or symptomatic PAD). Cholesterol values in mg/dL.
This calculator is for primary prevention only — patients without prior MI, stroke, TIA, or symptomatic PAD. It should not be used for patients with existing ASCVD (who already have a guideline indication for statin therapy). The PCE were derived for non-Hispanic White and African American adults; estimates for other populations may be less accurate.
Understanding the Pooled Cohort Equations
The Pooled Cohort Equations (PCE) were developed by the ACC/AHA Risk Assessment Work Group and published in the 2013 Guideline on the Assessment of Cardiovascular Risk. They were derived from several large, racially diverse NHLBI-sponsored cohort studies — including ARIC, the Cardiovascular Health Study, CARDIA, and the Framingham Original and Offspring cohorts — encompassing over 24,000 participants followed for a median of 12 years.
The equations use sex- and race-specific Cox proportional hazards models to estimate the 10-year probability of a first “hard” ASCVD event: non-fatal MI, CHD death, or fatal or non-fatal stroke. Input variables are age, total cholesterol, HDL cholesterol, systolic blood pressure (with treated/untreated status), diabetes, and current smoking status. All continuous variables enter the model as natural logarithms, with interaction terms between age and several risk factors to capture the differential impact of these factors at different ages.
Model Structure
Risk = 1 − S₀exp(ΣβX − mean)
Where S₀ is the baseline 10-year survival, ΣβX is the sum of coefficient × risk factor values, and “mean” is the population mean coefficient value. Four separate equations are used for White women, African American women, White men, and African American men.
Input Variables
Age (40–79 years)
Sex (male / female)
Race (White / African American)
Total cholesterol (mg/dL)
HDL cholesterol (mg/dL)
Systolic BP (mmHg) + treated status
Diabetes (yes / no)
Current smoker (yes / no)
Key distinction: The PCE replaced the older Framingham Risk Score in US guidelines. Unlike Framingham, the PCE include stroke as an endpoint, incorporate race-specific equations, and were derived from a broader population base. The 2023 AHA PREVENT equations have been proposed as an updated successor, adding kidney biomarkers and social deprivation index while removing race as a variable.
Risk Categories & Interpretation
| 10-Year Risk | Category | 2019 ACC/AHA Recommendation |
|---|---|---|
| < 5% | Low | Focus on lifestyle; statin generally not recommended for primary prevention |
| 5% – < 7.5% | Borderline | Risk discussion; statin may be considered if risk-enhancing factors present |
| 7.5% – < 20% | Intermediate | Moderate-intensity statin recommended if risk discussion favours treatment; consider CAC score if decision uncertain |
| ≥ 20% | High | High-intensity statin recommended to reduce LDL-C by ≥ 50% |
The 7.5% threshold triggers a clinician-patient risk discussion about statin therapy, but it is not an automatic treatment threshold. The 2019 ACC/AHA guidelines emphasise shared decision-making, incorporating the patient’s preferences, potential adverse effects, drug interactions, and the presence of risk-enhancing factors. When the decision is uncertain, a coronary artery calcium (CAC) score of 0 Agatston units may reasonably defer statin therapy.
Risk-Enhancing Factors
The 2019 ACC/AHA guidelines identify several risk-enhancing factors that favour statin initiation in borderline- and intermediate-risk patients. These factors are not included in the PCE calculation but should be considered in the clinician-patient risk discussion.
- Family history of premature ASCVD — first-degree male relative < 55 years or female relative < 65 years with MI, stroke, or sudden cardiac death
- Persistently elevated LDL-C ≥ 160 mg/dL (4.1 mmol/L) — particularly in younger adults, may suggest familial hypercholesterolaemia
- Metabolic syndrome — defined by ≥ 3 of: increased waist circumference, elevated triglycerides (≥ 150 mg/dL), low HDL-C, elevated BP, elevated fasting glucose
- Chronic kidney disease — eGFR 15–59 mL/min/1.73 m² (not on dialysis)
- History of pre-eclampsia or premature menopause (before age 40)
- hs-CRP ≥ 2.0 mg/L — persistent elevation after excluding acute infection; reflects chronic systemic inflammation
- Lp(a) ≥ 50 mg/dL or ≥ 125 nmol/L — genetically determined, independent ASCVD risk factor
- ApoB ≥ 130 mg/dL — particularly useful when triglycerides are elevated and LDL-C may underestimate atherogenic particle burden
- Ankle-brachial index (ABI) < 0.9 — indicates subclinical peripheral arterial disease
- South Asian ancestry — associated with higher ASCVD risk than PCE may estimate; the White equations are used but may underestimate risk
- Chronic inflammatory conditions — rheumatoid arthritis, psoriasis, lupus, HIV — confer excess cardiovascular risk beyond traditional risk factors
- Persistently elevated triglycerides ≥ 175 mg/dL — marker of atherogenic dyslipidaemia and insulin resistance
The presence of one or more risk-enhancing factors should lower the threshold for statin initiation, particularly in the borderline (5–7.5%) and intermediate (7.5–20%) risk groups.
Statin Therapy Guidance by Risk
Four statin benefit groups (2018 ACC/AHA): (1) Clinical ASCVD — high-intensity statin. (2) LDL-C ≥ 190 mg/dL — high-intensity statin. (3) Diabetes, age 40–75, LDL-C 70–189 — moderate-intensity statin (high-intensity if multiple risk factors). (4) Primary prevention, age 40–75, LDL-C 70–189, 10-year risk ≥ 7.5% — moderate-to-high intensity statin after risk discussion.
Common Pitfalls & Limitations
Multiple external validation studies have suggested that the PCE may overestimate 10-year ASCVD risk in some populations, potentially by 20–60%. The derivation cohorts were recruited before 2000, when ASCVD event rates were higher than in contemporary populations benefiting from improved hypertension control, statin use, smoking cessation, and lifestyle changes. This overestimation may result in more patients being recommended statin therapy than would truly benefit.
How to mitigate: When the PCE risk estimate sits near a treatment threshold (e.g., 7.5% or 20%), consider using coronary artery calcium (CAC) scoring to refine the estimate. A CAC score of 0 indicates very low near-term risk regardless of the PCE result.
The PCE were derived and validated only in non-Hispanic White and African American populations. For Hispanic, Asian, Native American, and other racial/ethnic groups, the White equations are applied as a default, but their calibration in these groups is uncertain. The equations may underestimate risk in South Asian populations and overestimate risk in East Asian and Hispanic populations.
How to mitigate: For patients of non-White, non-African American backgrounds, use the PCE result as an approximate starting point but give extra weight to risk-enhancing factors, family history, and subclinical atherosclerosis markers (CAC, ABI). The 2023 AHA PREVENT equations remove race as a variable and may provide better calibration in diverse populations.
The PCE are exclusively for primary prevention — estimating first-event risk in patients who have never had an ASCVD event. Patients with existing clinical ASCVD (prior MI, stroke, TIA, symptomatic PAD, prior revascularisation) already have a guideline indication for high-intensity statin therapy and do not need a risk calculator. Using the PCE in these patients is inappropriate and the results are not validated.
How to avoid: Before calculating, confirm the patient has no history of clinical ASCVD. If they do, initiate high-intensity statin therapy per secondary prevention guidelines without the calculator.
The PCE output is a population-level probability estimate, not a deterministic prediction for the individual. A 10-year risk of 8% does not mean the patient will definitely have an event — it means that in a population of similar individuals, approximately 8 out of 100 would be expected to have an event within 10 years. Over-reliance on the number without shared decision-making undermines the purpose of risk assessment.
How to avoid: Present the risk to the patient in the context of a discussion about their values, preferences, and concerns. Use visual aids (e.g., “8 out of 100 people like you”), discuss both absolute risk reduction with treatment and potential side effects, and respect the patient’s autonomy in the final decision.
Quick Reference Summary
| Risk Category | 10-Year Risk | Key Action |
|---|---|---|
| Low | < 5% | Lifestyle modification; reassess in 4–6 years |
| Borderline | 5 – < 7.5% | Risk discussion; statin if risk-enhancers present |
| Intermediate | 7.5 – < 20% | Moderate-intensity statin after shared decision-making; consider CAC if uncertain |
| High | ≥ 20% | High-intensity statin to reduce LDL-C ≥ 50% |
The Golden Rule: The ASCVD risk estimate initiates a conversation, not a prescription. Use it to frame the risk discussion, incorporate risk-enhancing factors and patient preferences, and leverage CAC scoring when the decision is uncertain — particularly around the 7.5% threshold.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129(25 Suppl 2):S49-S73. DOI: 10.1161/01.cir.0000437741.48606.98
- Arnett DK, Blumenthal RS, Baber B, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646. DOI: 10.1161/CIR.0000000000000678
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. DOI: 10.1161/CIR.0000000000000625
- Muntner P, Colantonio LD, Cushman M, et al. Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations. JAMA. 2014;311(14):1406-1415. DOI: 10.1001/jama.2014.2630
- Yadlowsky S, Hayward RA, Sussman JB, et al. Clinical implications of revised Pooled Cohort Equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169(1):20-29. DOI: 10.7326/M17-3011
- Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the AHA. Circulation. 2023;148(24):1982-2004. DOI: 10.1161/CIR.0000000000001191
- Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from SCCT. J Cardiovasc Comput Tomogr. 2017;11(2):157-168. DOI: 10.1016/j.jcct.2017.02.010
- DeFilippis AP, Young R, Carrillo-Larco RM, et al. Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in clinical practice. JACC. 2023;82(17):1722-1735. DOI: 10.1016/j.jacc.2023.07.018